Caribou Biosciences (CRBU) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Caribou Biosciences (CRBU) over the past year, gaining 34.5% versus a loss of 83.3%. Over five years, EDSA leads with a -93.6% price change compared with -97.8% for CRBU. Caribou Biosciences is the larger company by market cap ($49.3 million vs $47.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | EDSA |
|---|---|---|
| Share price | $0.4602 | $3.51 |
| Market cap | $49.34M | $47.43M |
| 1-day change | -4.36% | -4.10% |
| YTD return | -71.06% | +147.18% |
| 1-year return | -83.27% | +34.48% |
| 5-year return | -97.79% | -93.58% |
| EPS (TTM) | $-1.08 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $20.32 |
| 52-week low | $0.4425 | $0.72 |
| Distance from 52-week high | -86.98% | -82.73% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1149.46% | +365.24% |
| Average volume | 2.14M | 62.07K |
| Shares outstanding | 107.21M | 13.51M |
| Employees | 97 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed CRBU by 117.7 percentage points over the past year.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
CRBU vs EDSA FAQ
Which is bigger, Caribou Biosciences or Edesa Biotech?
Caribou Biosciences (CRBU) is larger, with a market capitalization of $49.34M compared with $47.43M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, CRBU or EDSA?
EDSA returned +34.48% over the past 12 months, compared with -83.27% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Edesa Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Caribou Biosciences and Biotechnology: Pharmaceutical Preparations for Edesa Biotech.